Antiarrhythmic Effect of H-2 Antihistamines
To the Editor:
Histamine, since its isolation from ergot,1 has been recogni/.ed to possess arrhythmogenic activity. This property is considered to be mostly due to 111 receptor-mediated slowing of atrioventricular conduction and 112-mediated increase in sinus rate and ventricular automatic-it}'.23 Cellular events, which parallel the alx>ve effects, include activa tion of adenylate cyclase of cyclic adenosine monophosphate* and the generation ol an inward (Ca' f) current due to opening of slow channels. 5 Clinical conditions where histaininc's arrhythmogenesis has IH-CII recogni/ed include secondary disorders of the heart such as anaphylaxis'1 and drug reactions.712
The authors tried to determine whether ventricular arrhythmias associated witli primary myocardial diseases could have been mediated by cardiac histamine release.
Myocardial mast cells were examined by light (toluidine blue stain) and electron microscopy in biopsy fragments from ten patients with complex ventricular arrhythmias (Lown 3-4B) who underwent ventricular endomyocardial biopsy (three to five biopsies per patient) for histologic evaluation.
Cardiac contractility was normal (LVEF >0.50) in four patients, moderately depressed (LVEF between 0.40 and 0.50) in four patients, and severely compromised (LVEF 0.20 and 0.25, respec tively) in two. In every case, the valvular pattern, coronary network, plasma electrolytes (Na', K', Ca*', Mg*'), and thyroid function test results were within normal limits. In this patient population, cardiac histamine (II) release, was also evaluated in simultaneous blixMJ samples from the aorta (Ha) and coronary sinus (lies) taken at the beginning of cardiac catheteri/ation (in order to avoid possible interference due to biopsy and angiography). Histamine level was then determined by fhioronefelometric method using a TechniconAutoanaly/.er2 after blood samples were treated with perchloric acid. Our study included evaluation of antiarrhythmic effect of 112-antihistamines, monitoring (24-h Holler) cardiac rhythm before and after 5 days of therapy with 1 g/day cimetidine.
Histologic results provided evidence of myocarditis in six patients (healing in four; healed in two) and of cardiomyopathic changes in four cases.
Myocardial mast cells were significantly increased (6 Â± 3/section) and partially degrannlated at nltrastructiiral examination in patients with myocarditis, compared with cardiomyopathic patients (1 Â±I/ section) and normal control subjects (four patients undergoing surgery for atrial septal delect) (1 Â±I/section).
As far as cardiac histamine is concerned, lies was found to be 10-30 percent higher (8Â±1.4 \ip/m\) than Ha (6Â±1.2 jig/ml, confidence <().! (jLg/ml) in patients with myocarditis, while un changed lies vs II values were observed in the cardiomyopathy group.
Analysis of cardiac rhythm revealed, following cimetidine treat ment, reduction >80 percent of ventricular extrasystolic l>eats in four of six and >50 percent in two of six patients with myocarditis, and no response of ventricular extrasystoles associated with cardio myopathy.
In conclusion, in patients with ventricular arrhythmias and histologic evidence of myocarditis our data document: 1) increased number and degranulation of myocardial mast cells; 2) rise of myocardial histamine release; and 3) susceptibility of ventricular arrhythmias to H2-antihistamines. xxxvin-xxxix In a similar case involving methyl chloroform (MCF), we extensively investigated the phosgene theory but with a frustrating outcome, illustrating the inherent problems of retro spective exposure assessment.
A 62-year-old skilled welder who was a smoker was admitted to hospital on March 1, 1981 with fever (38.6Â°C)and severe respiratorydistress. Initially, myocardial infarction or Legionella pneumonia was suspected, but these diagnoses were later discarded. Instead, toxic pulmonary edema with secondary fibrosis was suspected. The patient was treated in a respirator with positive end-expiratory pressure, but his condition remained unstable and he could not be disconnected from the respirator until the end of April. However, due to recurrent gastrointestinal bleeding (probably due to the massive steroid treatment in combination with metabolic stress) the patient died on May 20. The underlying cause of death based on a medico-legal autopsy was phosgene intoxication.
When this case was revealed to us after one week of hospital care, several attempts were made to find the cause. However, we were not able to interview the welder in person.
During three consecutive days ending February 27, the patient had been welding mild (carbon) steel items covered with a drawing oil containing 1.7 percent chlorine. A consumable electrode and a 4:1 mixture of argon/carbon dioxide metal inert gas was used. Lack of time forced him to use an MCF formula stabilized with dioxane for on-site degreasing between welding operations. The welding was performed in a corner of a voluminous (approx. 40,000 cu mm) workshop with fairly simple general and local ventilation. On the night between February 27 and 28 he started to feel "uneasy". At lunchtime on February 28 he was shivering and his body tempera ture was 40.5Â°C.According to his wife, he had recognized symptoms of "intoxication"
(possibly alluding to metal fume fever). The situation progressed with a severe dyspnea and some instances of diarrhea; the next morning he was taken to the hospital.1
During a work site reconstruction one month after the incident, no phosgene could be detected using reagent tubes (Drager; detection limit 0.05 ppm), not even at high MCF levels (maximum 740 ppm).2 In a separate experiment with the reagent tulies. Although no technical support for a toxic phosgene exposure could be found in this particular case, the overall evidence suggests that this nevertheless was an example of toxic pulmonary edema following welding in the presence of a chlorinated solvent. The combination should always be discouraged.
How Long Do Patients with Cor Pulmonale Secondary to Pulmonary Fibrosis Survive?
The mortality rate in patients with cor pulmonale secondary to chronic obstructive pulmonary disease (COPD) is well documented. The 6 months-1 year survival rate (despite intensive medical treatment) is generally very poor: approximately 30 to 35 percent.1"4
To our knowledge, there is very little information on the mortality rate of patients with cor pulmonale secondary to pulmonary fibrosis (PF) alone or in association with COPD. Pulmonary fibrosis is a common sequela of repeated and improperly treated lower respi ratory bacterial, viral, protozoal, and mycobacterial infections during childhood and early adulthood, especially in developing
